Kennesaw State Publishes THC Brain Research, Alzheimer's Drug Studies

Dual Publication Advances University's Cannabis Neuroscience Profile

Kennesaw State University's neuroscience lab released two separate peer-reviewed papers examining THC brain effects and Alzheimer's drug mechanisms. The research team, based at the university's Marietta campus, focused one study on cannabinoid receptor activity during THC exposure. A second tackled therapeutic targets for Alzheimer's disease progression.

The THC study examined neural pathway responses in controlled exposure scenarios. Researchers tracked receptor binding patterns and synaptic changes across different dosage levels. The Alzheimer's work explored how existing drug candidates interact with beta-amyloid plaques and tau protein tangles, the two hallmark pathologies of the disease.

Both papers underwent standard peer review before publication in neuroscience journals. The university didn't disclose funding sources or pharmaceutical partnerships in its initial announcement.

Research Methodology and Scope

The THC exposure study used in-vitro brain tissue models to isolate cannabinoid receptor responses without confounding variables. This approach lets researchers observe THC's direct neurological effects at the cellular level, separate from systemic metabolic processes.

Key research parameters included:

• Controlled THC concentration ranges from 1 to 50 micromolar
• CB1 and CB2 receptor activation tracking via fluorescent tagging
• Synaptic plasticity measurements over 72-hour exposure windows
• Comparative analysis against CBD and synthetic cannabinoid controls

Different model for the Alzheimer's drug research. That team tested how FDA-approved dementia medications interact with cannabinoid pathways, exploring whether THC or CBD might enhance or interfere with existing treatments.

Implications for Medical Cannabis Research Pipeline

These publications position Kennesaw State as a contributor to the growing body of U.S.-based cannabis neuroscience work, which remains constrained by federal Schedule I restrictions. Universities conducting cannabis research typically rely on NIDA-supplied material or state-licensed partnerships where legal frameworks permit.

Georgia's medical cannabis law allows low-THC oil production but restricts research pathways. Kennesaw State's ability to publish peer-reviewed THC studies suggests either federal DEA research registration or collaboration with institutions holding Schedule I licenses.

The Alzheimer's angle carries commercial weight. Pharmaceutical companies developing dementia therapeutics now routinely screen drug candidates for cannabinoid pathway interactions after several high-profile clinical trial failures linked to unexpected receptor cross-reactivity. Understanding how THC affects Alzheimer's drug efficacy could inform dosing protocols for the 6.7 million Americans living with the disease.

For background on cannabis neuroscience developments, see the CannIntel topic hub on THC brain research.